Clinical Trial Update: GDP in Frontline Chemotherapy for Patients With PTCL-NOS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating GDP (gemcitabine, cisplatin, dexamethasone) as frontline chemotherapy for peripheral T-cell lymphoma not otherwise specified (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• CISPLATIN (cisplatin)
• DEXAMETHASONE (Dexamethasone)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Lymphoma, T-Cell, Peripheral | Phase 2 | Status: UNKNOWN